0001213900-22-075598.txt : 20221128
0001213900-22-075598.hdr.sgml : 20221128
20221128182758
ACCESSION NUMBER: 0001213900-22-075598
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221123
FILED AS OF DATE: 20221128
DATE AS OF CHANGE: 20221128
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Erfanian Hamid
CENTRAL INDEX KEY: 0001893172
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-09974
FILM NUMBER: 221427623
MAIL ADDRESS:
STREET 1: 527 MADISON AVENUE
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ENZO BIOCHEM INC
CENTRAL INDEX KEY: 0000316253
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071]
IRS NUMBER: 132866202
STATE OF INCORPORATION: NY
FISCAL YEAR END: 0731
BUSINESS ADDRESS:
STREET 1: 60 EXECUTIVE BLVD
CITY: FARMINGDALE
STATE: NY
ZIP: 11735
BUSINESS PHONE: 5167555500
MAIL ADDRESS:
STREET 1: ENZO BIOCHEM INC
STREET 2: 60 EXECUTIVE BLVD
CITY: FARMINGDALE
STATE: NY
ZIP: 11735
4
1
ownership.xml
X0306
4
2022-11-23
0
0000316253
ENZO BIOCHEM INC
ENZ
0001893172
Erfanian Hamid
C/O ENZO BIOCHEM, INC
81 EXECUTIVE BLVD., SUITE 3
FARMINGDALE
NY
11735
1
1
0
0
Chief Executive Officer
Common Stock, $0.01 Par Value
2022-11-23
4
P
0
100000
1.97
A
374600
D
Stock Option (to acquire Common Stock)
1.97
2022-11-23
4
A
0
300000
0
A
2023-11-23
2027-11-23
Common Stock
300000
300000
D
Stock Option (to acquire Common Stock)
3.39
2022-11-08
2026-11-08
Common Stock
700000
700000
D
The Reporting Person was granted Restricted Stock Units that will vest in three equal installments, beginning on November 23, 2023.
The Reporting Person was granted 300,000 stock options. The stock options have a five-year term and will vest, subject to the individual's continued employment with Enzo Biochem, Inc., in three equal annual installments, beginning on November 23, 2023.
The Reporting Person was granted 700,000 stock options. The stock options have a five-year term and will vest, subject to the individual's continued employment with Enzo Biochem, Inc., in three equal annual installments, beginning on November 8, 2022.
/s/ Hamid Erfanian
2022-11-28